USPTO serial 98023899
RPI RIVIERA PHARMA INC
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- CALI, KRISTIN K
- Law office
- TMO LAW OFFICE 131- EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with RPI RIVIERA PHARMA INC?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Mark C. Johnson
MARK C. JOHNSON JOHNSON | DALAL111 NORTH PINE ISLAND ROAD, SUITE 105PLANTATION, FL 33324UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Gauze; Aloe vera gel for therapeutic purposes; Aloe vera preparations for pharmaceutical purposes; Aloe vera preparations for therapeutic purposes; Antiseptic cotton; Antiseptic preparations; Antiseptic wipes; Antiseptics; Bandages for dressings; Bandages for skin wounds; Buccal tablets for medical use for use in the treatment of Cancer, Infections, Endocrine disorders and conditions, Cardiovascular disease, Immunological conditions and disorder, Kidney disease, Liver disease, Diabetes, Autoimmune diseases, Traumatic Injuries, Psychiatric conditions, Lung disease, Skin disorders, transplanted organs, neurological disorders and conditions, Immunosuppression, and any known current diseases or any new discovered diseases that may arrive in the future; Burn relief medication; Chemical preparations for pharmaceutical or medical purposes, namely, for Cancer, Infections, Endocrine disorders and conditions, Cardiovascular disease, Immunological conditions and disorder, Kidney disease, Liver disease, Diabetes, Autoimmune diseases, Traumatic Injuries, Psychiatric conditions, Lung disease, Skin disorders, transplanted organs, neurological disorders and conditions, Immunosuppression, and any known current diseases or any new discovered diseases that may arrive in the future; Cotton for medical purposes; Cotton sticks for medical purposes; Cotton swabs for medical purposes; Cotton swabs for medical use; Cotton wool for medical purposes; Eucalyptus for pharmaceutical purposes; Eye drops; First aid kits; First aid kits for domestic or other non-professional use; Intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; Medical preparations for the treatment of Cancer, Infections, Endocrine disorders and conditions, Cardiovascular disease, Immunological conditions and disorder, Kidney disease, Liver disease, Diabetes, Autoimmune diseases, Traumatic Injuries, Psychiatric conditions, Lung disease, Skin disorders, transplanted organs, neurological disorders and conditions, Immunosuppression, and any known current diseases or any new discovered diseases that may arrive in the future; Medicated lip balm; Medicated lip balm containing beeswax; Medicated lip balms; Nasal and oral spray preparations for use as central nervous system stimulants; Nasal cleaning preparations for medical purposes; Nasal drops for the treatment of allergies; Nasal rinse; Nasal spray preparations; Nasal sprays for medical purposes; Preparations for the treatment of asthma; Preparations for the treatment of burns; Saline solution for medical purposes; Saline solution for sinus and nasal irrigation; Saline wash for medical purposes; Sinus pillows containing aromatic substances for relief from headaches, insomnia and sinus discomfort; Throat lozenges; Vaccine adjuvants; Vaccine preparations; Vaccine stabilizers; Vaccines; Vaccines against flu; Vaccines against pneumococcal infections; Vaccines against viral infection; Vaccines for human use; Acne treatment preparations; Adhesive bandages; Adhesive tapes for medical purposes; Adhesive for bandages for skin wounds; Anti-drowsiness treatment preparations; Antibacterial/antimicrobial tape for the purpose of destroying bacteria, mold and mildew; Antiseptic liquid bandages; Aseptic cotton; Biological preparations for the treatment of cancer; Burn dressings; Cardiovascular treatment preparations; Cold sore treatment preparations; Concentrated saline capsules for sinus and nasal irrigation; Cough treatment preparations; Decongestant nasal sprays; Dry ingredients for making a saline solution for sinus and nasal irrigation; Dysmenorrhea treatment preparations; Ear bandages; Eye pillows containing aromatic substances for relief from headaches, insomnia and sinus discomfort; Fever blister treatment preparations; Gastro-intestinal treatment preparations; Gauze for dressings; Headache treatment preparations; Hemorrhoid treatment preparations; Herbal products, namely, aromatherapy packs containing herbs used for relief from headaches, insomnia and sinus discomfort; Human vaccine preparations; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Liquid bandage sprays; Liquid bandages for skin wounds; Medical dressings; Medical adhesive tape; Medical and surgical dressings; Medicated mouth treatment preparations; Medicated mouth care and treatment preparations; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Migraine treatment preparations; Mixed biological preparations for the prevention and treatment of infectious diseases; Motion sickness treatment preparations; Nail fungus treatment preparations; Natural remedy preparations for the treatment of gastro-intestinal conditions, hormonal and chemical imbalances, and sleep disorders; Nausea treatment preparations; Niacinamide preparations for the treatment of acne; Oral vaccine preparations; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical preparations for the treatment of bone fractures; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hypercholesteremia; Pharmaceutical preparations for the treatment of hyperlipidemia; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for the treatment of viral diseases; Pharmaceutical preparations for the treatment of viral infections; Pharmaceutical preparations for the treatment of Cancer, Infections, Endocrine disorders and conditions, Cardiovascular disease, Immunological conditions and disorder, Kidney disease, Liver disease, Diabetes, Autoimmune diseases, Traumatic Injuries, Psychiatric conditions, Lung disease, Skin disorders, transplanted organs, neurological disorders and conditions, Immunosuppression, and any known current diseases or any new discovered diseases that may arrive in the future; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders; Self adhesive dressings; Solvents for removing adhesive bandages; Sponges impregnated with antiseptics; Sterilized dressing; Surgical bandages; Surgical dressings; Surgical tape; Therapeutic vaccines; Viral vaccines; Wound dressings | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 11, 2024 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jun 11, 2024 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Feb 26, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 26, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 26, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 23, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 7, 2023 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Jul 6, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 5, 2023 | NWAP | NEW APPLICATION ENTERED | — |